Glioblastoma Multiforme, Glioblastoma, GBM
Conditions
Brief summary
New treatments are greatly needed for patients with recurrent glioblastoma. Metronomic temozolomide is a standard treatment option but has, at best, modest activity. The nanoliposomal irinotecan may be much more active than the parent compound irinotecan since nanoliposomal irinotecan's ability to cross the blood brain barrier is improved. This phase I study will establish the MTD of the combination of nanoliposomal irinotecan in combination with temozolomide safety and preliminary clinical efficacy of the combination of nanoliposomal irinotecan and metronomic temozolomide.
Detailed description
1.1 Primary Objective 1.1.1. To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. 1.1.2 To assess the preliminary response rate and progression free survival of nanaliposomal irinotecan with continuous low-dose temozolomide in patients with recurrent glioblastoma. 1.2 Secondary Objectives 1.2.1 To evaluate the safety of nanoliposomal irinotecan with continuous low-dose temozolomide.
Interventions
Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
DRUGTemozolomide
Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
Sponsors
Merrimack Pharmaceuticals
Rhode Island Hospital
Brown University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed glioblastoma multiforme (gliosarcoma also eligible), Pathology report to be sent to BrUOG. * Progression or recurrence after at least one line of therapy. Patient must have received temozolomide and radiation but it is not required that they were given concurrently. * Age \>18 years * Karnofsky performance score \> 60 * Life expectancy \>12 weeks as noted by treating investigator * Laboratory results requirements * Absolute neutrophil count (ANC) ≥ 1500/mm3. * Platelets (Plt) ≥ 100,000/mm3 * Hemoglobin (Hgb) ≥ 9.0 g/dL * Total bilirubin \< 1x ULN * Albumin levels ≥ 3.0 g/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 x ULN * Not pregnant and not nursing. Women of child bearing potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to Day 1 of treatment. Post-menopausal women (surgical menopause or lack of menses \>12 months) do not need to have a pregnancy test, please document status. * Confirmation of informed consent. * Men and women of childbearing potential enrolled in this study must agree to use adequate barrier birth control measures during the course of the study and for at least 2 months after the last treatment on study. * Recovered (\< grade 1) from clinically significant effects of any prior surgery, radiotherapy or other anti-neoplastic therapy, except alopecia or hematological laboratory values * Stable corticosteroid dose at least 7 days prior to day 1 * Patients must have assessable (measurable) disease at baseline by brain MRI. Must be contrast enhancing. The tumor size will be measured in millimeters and is the largest cross-sectional area using perpendicular measurements of contrast enhancing abnormality. * Patient must be able to tolerate brain MRI with contrast
Exclusion criteria
* Non-GBM primary invasive malignant neoplasm that is considered by treating investigator to likely cause death in the next 5 years. * Radiation therapy or cytotoxic chemotherapy or biologics or immunotherapy within previous three weeks from day 1 of drug (no anticancer treatment of any kind within 3 weeks of day 1 of drug- steroids are acceptable if stable dose per 3.1.11). * Patients not to be receiving any cancer therapy or investigational anti-cancer drug. * Evidence of an active infection requiring intravenous antibiotic therapy * Any medical condition that in the opinion of the Investigator may interfere with a subject's participation in or compliance with the study. Must receive confirmation in writing from treating MD. * Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment based on serum pregnancy test. * Unwillingness or inability to follow the procedures required in the protocol, site to have documentation to confirm at time of registration that this is not the case. * Patient with a history of Gilbert's disease or known UGT1A1\*28 allele. (Assessment for the UGT1A1\*28 allele is not required for protocol entry.) Documentation required at time of study entry by treating MD. * myocardial infarction, unstable angina pectoris, stroke within 6 months of study registration. * NYHA Class III or IV congestive heart failure * Known hypersensitivity to any of the components of nanoliposomal irinotecan , other liposomal products, or temozolomide. Must be documented by treating MD. * Investigational anticancer therapy administered within 4 weeks of day 1, or within a time interval less than at least 5 half lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study. Site must submit all prior investigational agents with last dose administered and half-life for BrUOG review. * Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed. All recent vaccines (within 30 days) to be listed on conmed log and submitted to BrUOG. * Use of strong CYP3A4 inducers is not allowed and patients must be off any of these exclusionary products for \> 2 weeks from day 1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of Maximum Tolerated Dose (MTD) | Every two weeks for 4 weeks | To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. |
| Response | Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years. | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma. | Collected every 3 months once treatment has stopped, until progression of disease, up to 2 years. | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicities | Baseline through 30 days post off study treatment | Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose 1 Temozolomide: 50mg/m2/day until disease progression.
Nanoliposomal irinotecan :
Dose Level 1 50mg/m2 IV every 2 weeks | 9 |
| Dose 2 Temozolomide: 50mg/m2/day until disease progression.
Nanoliposomal irinotecan :
Dose Level 2 70 mg/m2 IV every 2 weeks | 3 |
| Total | 12 |
Baseline characteristics
| Characteristic | Dose 2 | Total | Dose 1 |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 3 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 9 Participants | 7 Participants |
| Age, Continuous | 64 years | 56 years | 54 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 11 Participants | 8 Participants |
| Region of Enrollment United States | 3 participants | 12 participants | 9 participants |
| Sex: Female, Male Female | 1 Participants | 2 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 10 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 8 / 9 | 2 / 3 |
| other Total, other adverse events | 9 / 9 | 3 / 3 |
| serious Total, serious adverse events | 4 / 9 | 3 / 3 |
Outcome results
Primary
Determination of Maximum Tolerated Dose (MTD)
To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma.
Time frame: Every two weeks for 4 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Determination of Maximum Tolerated Dose (MTD) | 50 mg/m^2 |
Primary
Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Response | Partial Response | 1 participants |
| All Participants | Response | Progressive Disease | 8 participants |
| Dose 2 | Response | Partial Response | 1 participants |
| Dose 2 | Response | Progressive Disease | 2 participants |
Primary
Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma.
Time frame: Collected every 3 months once treatment has stopped, until progression of disease, up to 2 years.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma. | Deceased | 8 Participants |
| All Participants | Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma. | Alive | 1 Participants |
| Dose 2 | Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma. | Deceased | 2 Participants |
| Dose 2 | Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma. | Alive | 1 Participants |
Secondary
Toxicities
Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4
Time frame: Baseline through 30 days post off study treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Toxicities | ALT/AST | 2 events |
| All Participants | Toxicities | Hypokalemia | 1 events |
| All Participants | Toxicities | Neutropenia | 0 events |
| All Participants | Toxicities | Hypophosphatemia | 1 events |
| All Participants | Toxicities | Nausea | 1 events |
| All Participants | Toxicities | Fatigue | 2 events |
| All Participants | Toxicities | Diarrhea | 0 events |
| All Participants | Toxicities | Anorexia | 0 events |
| All Participants | Toxicities | Dehydration | 0 events |
| All Participants | Toxicities | Urticaria | 1 events |
| Dose 2 | Toxicities | Anorexia | 2 events |
| Dose 2 | Toxicities | ALT/AST | 1 events |
| Dose 2 | Toxicities | Fatigue | 2 events |
| Dose 2 | Toxicities | Hypokalemia | 1 events |
| Dose 2 | Toxicities | Urticaria | 0 events |
| Dose 2 | Toxicities | Neutropenia | 1 events |
| Dose 2 | Toxicities | Diarrhea | 2 events |
| Dose 2 | Toxicities | Hypophosphatemia | 0 events |
| Dose 2 | Toxicities | Dehydration | 2 events |
| Dose 2 | Toxicities | Nausea | 2 events |